Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Bayoglu, Ibrahim; Kucukzeybek, Betul; Kucukzeybek, Yuksel; Varol, Umut; Yildiz, Ibrahim; Alacacioglu, Ahmet; Akyol, Murat; Demir, LÜTFİYE; Dirican, Ahmet; Yildiz, Yasar; Salman, Tarik; Tarhan, Mustafa

doi:10.1016/j.biopha.2015.01.019

Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers

Copy For Citation

Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz I., Alacacioglu A., ...More

BIOMEDICINE & PHARMACOTHERAPY, vol.70, pp.190-195, 2015 (SCI-Expanded)

Publication Type: Article / Article
Volume: 70
Publication Date: 2015
Doi Number: 10.1016/j.biopha.2015.01.019
Journal Name: BIOMEDICINE & PHARMACOTHERAPY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.190-195
Eskisehir Osmangazi University Affiliated: No

Abstract

Purpose: Mesothelin is a cell surface glycoprotein that is overexpressed in various malignancies. Recent studies have revealed that mesothelin plays an oncogenic role in tumor growth and drug resistance through the Wnt/NF-kappa B/PI3K/Akt signaling pathways. Herein, the expression of mesothelin in HER2-positive and triple-negative breast cancer (TNBC) has been correlated with prognosis.